Led by Ben Philpot, PhD, and Matt Judson, PhD, the new therapy was generally well-tolerated and prevented key signs of the condition in animal models.
CHAPEL HILL, NC Scientists at the UNC School of Medicine have reported in the journal JCI Insight encouraging early tests of a gene therapy strategy against Angelman syndrome, a neurodevelopmental disorder that features poor muscle control and balance, hard-to-treat epilepsy, and intellectual disabilities.
Angelman syndrome affects roughly one in every 20,000 children, and in the US alone it is thought that there are more than 15,000 people with the condition. There is no specific treatment, but scientists led by Ben Philpot, PhD, Kenan Distinguished Professor of Cell Biology and Physiology at UNC School of Medicine and Associate Director of the UNC Neuroscience Center, previously suggested that the best way to treat the disorder would be to restore function of the UBE3A gene in neurons, which has been lost in the brains of people with Angelman syndrome.
The genetics of Angelman syndrome are more complicated than classic single-gene disorders such as cystic fibrosis and sickle-cell anemia. Humans inherit one maternal and one paternal copy of most genes. Angelman syndrome arises in children whose maternal UBE3A copy has somehow been mutated or deleted. For reasons that arent fully clear, mature neurons normally express only the maternal copy of UBE3A; the paternal copy is effectively silenced. Thus, when the maternal copy is lost, the genes function is absent in neurons. Because UBE3A encodes a protein that helps regulate the levels of other important proteins, its absence severely disrupts brain development.
Compounding the complexity, neurons express two different variants or isoforms of UBE3A that vary slightly in length a short form and a long form in a ratio of about three short forms for every one long form.
Philpots team was able to craft a version of UBE3A that, when expressed by neurons, yields short and long forms of the UBE3A protein at a near-normal ratio. The scientists inserted their therapeutic UBE3A gene into a virus-derived carrier, or vector, engineered for reliable delivery to neurons. They injected a solution of this vector into hollow spaces, called ventricles, in the brains of newborn Angelman syndrome model mice, which lack the maternal copy of the mouse Ube3a gene. Like humans with Angelman syndrome, these mice fail to express UBE3A protein in their neurons and develop motor deficits, seizures, and other neurological symptoms in the first months of life.
Philpot and colleagues verified that vector-borne UBE3A became active in neurons throughout the Angelman model mouse brain just days after injection, at a level similar to that of the normal gene. This treatment restored motor skill-learning and the essential mouse behaviors of digging, burrowing, and nest-building. Untreated mice developed the usual Angelman-like impairments. The treated mice also did not become as susceptible as their untreated counterparts to experimentally induced epileptic seizures, and importantly, did not suffer any obvious negative side effects.
This was a proof-of-concept study, but if these early results were translated to the clinic, they would represent big improvements in the quality of life for individuals with Angelman syndrome, said study lead author Matt Judson, PhD, a research associate in the Philpot Lab, who performed most of the experiments.
The researchers plan to further develop their strategy, first with more tests in mice and monkeys to optimize dose and delivery methods, and ultimately, pending promising safety results, human clinical trials. If such a therapy were available, the researchers expect it might be able to deliver benefits to individuals of any age, but perhaps with varying benefits.
The range from birth to four years is probably ideal, but we think that whenever we can reinstate this genes function in the brain, were likely to see some improvements, Philpot said.
Along with Judson and Philpot, who was recently ranked as the worlds leading Angelman syndrome researcher, the JCI Insight paper was co-authored by Charles Shyng, Jeremy Simon, Courtney Davis, Mattijs Punt, Mirabel Salmon, Noah Miller, Kimberly Ritola, Ype Elgersma, David Amaral, and Steven Gray.
The research was supported by the Angelman Syndrome Foundation, and the National Institutes of Health (R01HD093771, R01MH120229, R01NS114086).
- Overview: Gene Structure - Holland-Frei Cancer Medicine ... - December 23rd, 2021
- Bluebird, Editas: Gene Editing Stocks Had A Tough Year. Will 2022 Be Better? - Forbes - December 23rd, 2021
- Triangle gene editing firms CEO: There is a revolution occurring in medicine - WRAL TechWire - December 23rd, 2021
- Integra Therapeutics Q&A: building next-generation gene editing tools - pharmaceutical-technology.com - December 23rd, 2021
- Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -... - December 23rd, 2021
- Gene Mutation Found that is Linked to the Development of Kidney Disease - Clinical OMICs News - December 23rd, 2021
- Vaccines are just the beginning for RNA. The technology is being tested on heart and liver diseases. - The Philadelphia Inquirer - December 23rd, 2021
- A look at prospects for the US gene therapy industry - BioPharma-Reporter.com - December 23rd, 2021
- Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of... - December 23rd, 2021
- Betagenon co-founder publishes that AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced... - December 23rd, 2021
- CUIMC Year in Review: Health News - Columbia University Irving Medical Center - December 23rd, 2021
- EP. 6B: Phenotypic Theranostics in the Future of Precision Medicine - Targeted Oncology - December 23rd, 2021
- Emendo Biotherapeutics and Seattle Children's Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe... - December 23rd, 2021
- Open letter to employees, technologists, professionals and physicians of the Optilab laboratory medicine clusters in Quebec - McGill University Health... - December 23rd, 2021
- First variant of concern evolved to evade immune system - EurekAlert - December 23rd, 2021
- Double vaccinated and still infected with Omicron? Heres how long you should isolate - The Indian Express - December 23rd, 2021
- Genetic Tests Prompt Therapy Adjustments in Epilepsy - Medscape - December 22nd, 2021
- How to Know What Strain of COVID-19 You Have - Do Doctors Know What Variant You Have? - Prevention.com - December 22nd, 2021
- Low expression of PLAT in Breast cancer | IJGM - Dove Medical Press - December 22nd, 2021
- Outlook on the Advanced Therapy Medicinal Products CDMO Global Market to 2028 - Rising Number of Clinical Trials for ATMP is Driving Growth -... - December 22nd, 2021
- MiNA Therapeutics Appoints Two Independent Directors With Extensive Industry Experience to Support Next Phase of Growth - BioSpace - December 22nd, 2021
- New gene therapy could provide cure for sickle cell disease, according to UAB study - The Mix - December 19th, 2021
- Durham gene therapy plant to help Pfizer develop treatments for rare diseases - WRAL Tech Wire - December 19th, 2021
- Researchers zero in on therapeutic target for aggressive uterine cancer - Michigan Medicine - December 19th, 2021
- Generation Bio shares halved as hemophilia gene therapy hunt goes back to square one - FierceBiotech - December 19th, 2021
- URMC & RIT faculty awarded patent for gene transfer technology that could transform cancer therapies - URMC - December 19th, 2021
- Very important pharmacogene variants in the Blang population | PGPM - Dove Medical Press - December 19th, 2021
- Gene Sequencing Market Research, Analysis and Global Study |Roche, Johnson & Johnson, Illumina, Thermo Fisher Scientific - Digital Journal - December 19th, 2021
- Global Gene Editing Market Research Report 2021 Featuring CRISPR, GenScript, Horizon Discovery Group, Integrated DNA Technologies and New England... - December 19th, 2021
- Association between the anti-aging protein klotho with sleep | IJGM - Dove Medical Press - December 19th, 2021
- Covid-19: 7 Nigeria returnees admitted to Chennais Kings Institute of Preventive Medicine for suspected - Free Press Journal - December 19th, 2021
- Tessera Therapeutics Adds New Executives to its Leadership Team as the Company Continues to Pioneer Gene Writing Technology as New Category in Genetic... - December 13th, 2021
- Rare gene mutation in some Black Americans may allow earlier screening of heart failure - National Institutes of Health - December 13th, 2021
- Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia... - December 13th, 2021
- On the hunt for new ALS drugs, researchers see progress, and a long road ahead - BioPharma Dive - December 13th, 2021
- Europe Cell and Gene Therapy Market Size to Reach Revenues of USD 2.9 Billion by 2026 - Arizton - PRNewswire - December 13th, 2021
- Researchers Dig Up Genes and Cells Related to Skull Formation in Mice - Genetic Engineering & Biotechnology News - December 13th, 2021
- Syrian refugee is thriving five years after last-gasp gene therapy - STAT - STAT - December 13th, 2021
- The perils of flawed research and the ivermectin debacle - Medical News Today - December 13th, 2021
- Roche launches the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision... - December 13th, 2021
- Why Does The COVID-19 Virus 'Escape' From Our Immune Systems? - Texas A&M University Today - December 13th, 2021
- Hydra DNA Reveals Theres More Than One Way to Regrow a Head - The New York Times - December 13th, 2021
- Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH... - December 13th, 2021
- Use of Race in Clinical Diagnosis and Decision Making: Overview and Implications - Kaiser Family Foundation - December 13th, 2021
- Identification of Significantly Expressed Gene Mutations for Automated Classification of Benign and Malignant Prostate Cancer - DocWire News - December 13th, 2021
- VUMC: Gene Discoveries Give New Hope To People Who Stutter - Cannon Courier - December 13th, 2021
- Relationship among Homocysteine, Inflammation in AIS | NDT - Dove Medical Press - December 13th, 2021
- Groundbreaking Experimental Compound Displays Effectiveness in Treating Symptoms of Autism and Alzheimers Disease - SciTechDaily - December 13th, 2021
- '90 Day Fianc: Before the 90 Days': Everything to Know About Alina's Rare Medical Condition Diastrophic Dysplasia - Showbiz Cheat Sheet - December 13th, 2021
- Cincinnati Children's teams up with CTI on cell and gene therapies - The Lane Report - December 7th, 2021
- Is 'personalised medicine' the future of healthcare? - Tatler - December 7th, 2021
- Francis Collins on medical advances, vaccine hesitancy and Americans' ill health : Shots - Health News - NPR - December 7th, 2021
- Gene Expression Analysis Market: Rise in the need for personalized medicine is likely to influence the global market - BioSpace - December 7th, 2021
- Atamyo Therapeutics Obtains First Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-100, its Gene Therapy to Treat Limb-Girdle... - December 7th, 2021
- Gyroscope Therapeutics Announces Appointment of Tony Adamis to Board of Directors - Business Wire - December 7th, 2021
- Tune Therapeutics Launches with Pioneering Epigenomic Control Platform to Master Gene Networks, Treat Broad Range of Diseases - PRNewswire - December 7th, 2021
- Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide)... - December 7th, 2021
- The top 10 health and medicine breakthroughs of 2021 - Popular Science - December 7th, 2021
- SNPs rs251124, rs2287926, and rs173686 with IA | NDT - Dove Medical Press - December 7th, 2021
- Potential New Therapeutic Option May Combat Drug Resistance in HER2+ Breast Cancer and Ovarian Cancer - Cancer Network - December 7th, 2021
- Penn's Medical Emergency Response Team, 'prepared for anything' | Penn Today - Penn Today - December 7th, 2021
- Gene Therapy May Reverse Hurler Syndrome, a Rare and Severe Illness in Kids - HealthDay - November 21st, 2021
- Immunosuppressants linked to severe reactions in people with common genetic profile - Stanford Medical Center Report - November 21st, 2021
- A video that originated on InfoWars is filled with falsehoods about COVID-19 vaccines - PolitiFact - November 21st, 2021
- Gene signature may give an upper hand in metastatic breast cancer - Baylor College of Medicine News - November 21st, 2021
- Lung cancer management in the era of precision medicine - Express Healthcare - November 21st, 2021
- Powerful gene-based testing by integrating long-range chromatin interactions and knockoff genotypes - pnas.org - November 21st, 2021
- Stoke Therapeutics Announces Presentations from the Company's Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting - Business... - November 21st, 2021
- European Commission approves Roche's Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer |... - November 21st, 2021
- Maternal cannabis use is associated with suppression of immune gene networks in placenta and increased anxiety phenotypes in offspring - pnas.org - November 21st, 2021
- Vertex Announces Reimbursement Agreement in Spain for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With... - November 21st, 2021
- Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled... - November 21st, 2021
- Gene Therapy and Genetic Engineering - MU School of Medicine - November 17th, 2021
- Gene editing: Great for medicine but ethical issues arise - November 17th, 2021
- Gene on, gene off: Chroma Medicine turns lights on with $125M to control gene expression with ex-Editas, Regeneron leaders - FierceBiotech - November 17th, 2021
- gene therapy | Description, Uses, Examples, & Safety ... - November 17th, 2021
- Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development - Yahoo Finance - November 17th, 2021
- CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes -... - November 17th, 2021
- 8 medical advances you may have missed during COVID-19 - AAMC - November 17th, 2021
- PNAS Papers on Woodrat Microbiome, Maternal Cannabis Use, Gene-Based Testing - GenomeWeb - November 17th, 2021